Biocon Q1FY27 Total Income at ₹4,391 Cr, Up 9%; Net Profit at ₹141 Cr
Biocon Limited reported Q1FY27 consolidated total income of ₹4,391 crore, up 9% YoY. Revenue from operations grew 10% to ₹4,336 crore, driven by Biopharma revenue up 17%. Net Profit was ₹141 crore, a 355% increase. EBITDA stood at ₹902 crore. The company also noted reduced interest costs by 23%.
The announcement details robust financial performance with significant year-on-year growth in key metrics like revenue and net profit. This directly impacts investor confidence and the company's valuation.
The company reported strong year-on-year growth in total income, revenue from operations, and a significant increase in net profit. Positive commentary from leadership regarding future growth and strategic investments also contributes to a positive sentiment.
Biocon Limited announced its consolidated financial results for the fiscal first quarter ended June 30, 2026. The company reported a total income of ₹4,391 crore, an increase of 9% year-on-year. Revenue from operations grew by 10% YoY to ₹4,336 crore, primarily driven by strong performance in the Biopharma business.
The Biopharma segment revenue increased by 17% year-on-year, with Biosimilars revenue growing 16% YoY to ₹2,855 crore and Generics revenue increasing 21% YoY to ₹760 crore. This growth was attributed to recent biosimilar and generic product launches in key markets. However, Services revenue saw a decrease of 16% YoY to ₹736 crore.
Consolidated EBITDA stood at ₹902 crore, with a margin of 21%. Net Profit before exceptional items was ₹145 crore, and reported Net Profit for the quarter was ₹141 crore, a significant increase of 355% compared to the previous year's ₹31 crore. Interest costs were reduced by 23% YoY to ₹213 crore following balance sheet strengthening measures.
Kiran Mazumdar-Shaw, Executive Chairperson, expressed confidence in long-term opportunities, particularly in North America, supported by a favorable policy environment for biosimilars and expanded manufacturing capabilities. Shreehas Tambe, CEO & Managing Director, highlighted the resilient performance, successful launches of new biosimilar and generic products, and regulatory approvals for new facilities. He anticipates growth momentum to accelerate in the second half of the fiscal year.
Separately, the company announced updates regarding its Board of Directors, with Bobby Parikh completing his term as Independent Director and Nicholas Haggar set to conclude his term at the upcoming AGM. Biocon also received several awards and recognitions for its sustainability initiatives and leadership.
What to do with a filing like this
Biocon Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Biocon Limited. Read the original for the full detail.